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Osteosarcoma (OS) is the most common primary malignancy of the skeleton of dogs and humans. OS arises most commonly in the metaphyseal region of long bones, within the medullary cavity, and penetrates the cortex of the bone to involve the surrounding soft tissues (Broadhead *et al.*, 2011).

In dogs OS represents 80 to 85% of bone tumors, most frequently affecting male dogs of medium to large breeds between 2-years and 12-years of age (Leonardi, 2003 and Leonardi *et al.*, 2014). In dogs 24% of OS typically affects the axial skeleton, while the involvement of the appendicular skeleton is rather high (\> 70% of cases) (Liu *et al.*, 1977). Here we investigated immunohistochemically the expression of Bcl-2, an important membrane protein involved in apoptotic/autophagic mechanisms and expressed in several premalignant and malignant lesions and which its role is still not clarified in spontaneous osteosarcoma (Leoncini *et al.*, 1993). Apoptosis is the so-called programmed cell death that occurs when the damaged cell is no longer able to activate the repair systems (Stergiou and Hengartner, 2004). This mechanism can be triggered by external stimuli such as chemical or physical agents, or endogenous stimuli such as cell turnover or remodelling during cellular development.

In tumor formation, apoptosis is usually inhibited and the cells involved undergo uncontrolled proliferation (Robert *et al.*, 2012) Autophagy is an evolutionarily conserved process that involves cellular self-eating (Mizushima *et al.*, 2008). This mechanism of stress adaptation and degrading acts of cytoplasmic contents, it is in fact physiologically activated under conditions of nutrient deficiency. The process is based on the formation of a vesicles which takes the name of autophagosome, capable of sequestering damaged and degraded cytoplasmic organelles (Brech *et al.*, 2009).

The tumor suppressor function operated by autophagy is mediated by scavenging of damaged oxidative organelles, thus preventing accumulation of toxic oxygen radicals that would cause the genome instability. However, in some cases autophagy can also promote the survival of cancer cells once tumors have developed. This is attributed to the ability of autophagy to promote cell survival under conditions of poor nutrient supply, as often faced by solid tumors and metastasizing cancer cells (Brech *et al.*, 2009).

Research works conducted on the study of the mechanism of autophagy in tumors has led to identifying the involvement of a family of proteins that are also involved in apoptosis mechanisms. This family of protein is called Bcl-2 and is localized on the outer mitochondrial membrane, already involved in the apoptotic mechanism (Levine *et al.*, 2008). They are part of a family of more than 15 different proteins that are grouped into two categories according to which play a role in pro-apoptotic or anti-apoptotic cells. The same differentiation was found in the autophagic mechanism, In fact it has been demonstrated that the anti-apoptotic proteins Bcl-2 and Bcl-X~1~ also have the ability to inhibit autophagy through binding to a specific domain, which takes the name of BH3, present on a protein known with the name of Beclin1 involved in the regulation of autophagy (Robert *et al.*, 2012).

In humans it was identified that autophagy had an important role in the development of bone cancer (Huang *et al.*, 2012) and might be interesting to investigate whether this mechanism, involved in the process that affects the human being, is equally involved in OS in canines.

The aim of this preliminary study was to evaluate the immunohistochemical expression of Bcl-2 in spontaneous canine osteosarcoma being known its role in cell proliferation and tumorigenesis.

Materials and Methods {#sec1-2}
=====================

Ten cases of spontaneous high grade canine osteoblastic non metastatic osteosarcoma have been used to investigate the immunohistochemical expression of Bcl-2 through the use of specific antibody. The biological samples was represented by tumors resection pieces from patients hospitalized in different Clinics in Italy.

Tumor's samples were fixed in 10% neutral buffered formalin and subsequently were subjected to decalcification for bone tissues composed by an aqueous solution of formic acid, hydrochloric and sulphuric acid in different parts, left at room temperature for a variable time in relation to the degree of daily decalcification. Samples were then processed using common histopathological techniques and stained with Hematoxylin and Eosin (H&E) stains were performed on 3-5μ sections. The histopathological diagnoses were done in conformity with criterions established in 1994 by WHO classification of bone tumors (Slayter *et al.*, 1994) ([Table 1](#T1){ref-type="table"}).

###### 

Clinical data of samples used for IHC investigation.

  Samples     Breed                 Sex      Age     Site
  ----------- --------------------- -------- ------- -----------------
  Sample 1    \-                    Female           Femur SX
  Sample 2    \-                    Male     13 yy   Hock
  Sample 3    Half-breed            Male     10 yy   Humerus DX
  Sample 4    Pittbull              Male     12 yy   Vertebrae T3-L3
  Sample 5    Miniature Schnauzer   Female   10 yy   Sternum
  Sample 6    Golden Retriever      Male     7 yy    Humerus
  Sample 7    Half-breed            Male     12 yy   Radius DX
  Sample 8    Lagotto               Male     2 yy    Humerus DX
  Sample 9    Bull Mastiff          Male     10 yy   Carpus
  Sample 10   Terranova             Female   7 yy    Radius

Immunohistochemistry (IHC) was performed using the Avidin Biotin Complex (ABCL-2) method (Abcam kit). Paraffin was removed with xylene and slides were dehydrated in sequential diluted ethanol and then rinsed in distilled water. To inhibit endogenous peroxidase activity the tissue sections were treated with 3% hydrogen peroxide in tris phosphate-buffered saline (PBS). Non-specific reactivity was blocked with the use of normal goat serum for 30 minutes. Investigations was performed on serial sections of 3-5 μm using monoclonal antibody mouse antihuman Bcl-2 (clone 124, dilution 1:100, Dako). Samples of normal canine tonsil were used as a positive control for Bcl-2.
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Histologically, all tumors were highly cellular with polyhedral cells with large nuclei and hypercromatic chromatin, frequent mitoses and prominent nucleoli associated with production of different amount of osteoid. Bcl-2 immunostaining showed homogeneous increasing expression in all cases investigated, compared with normal bone in all samples investigated ([Fig. 1](#F1){ref-type="fig"}).

![Bcl-2 expression in spontaneous canine osteoblastic osteosarcoma. Bcl-2 is expressed with prevalent cytoplasmic immunoreactivity by tumoral osteoblastic cells that appears in agglomerated well packed group of cells throughout the lamellar bone structures negative for Bcl-2 IHC as well as the upper isle of cartilage. IHC magnification ×20.](OpenVetJ-5-27-g001){#F1}

The percentage of immunohistochemically positive cells in all cases investigated ranged from 80% to 95%. Fluorescence was always in the cytoplasm, consistent with normal mitochondrial membrane activity.

Discussion {#sec1-4}
==========

Bcl-2 is a protein belonging to a family that regulates different mechanisms of cell biology like autophagy and apoptosis (Yip and Reed, 2008). Bcl-2 is an anti-apoptotic protein that may protect cells from a variety of apoptotic stimuli, including cytotoxic drugs, irradiation, heat or growth factor withdrawal (Creagh *et al.*, 2000). The over expression of Bcl-2 has been described in different types of human tumors, including breast, colon, ovary and prostate cancers (Amundson *et al.*, 2000).

Although Bcl-2 confers resistance to malignant cells, it does not always correlate with poor prognosis (Hassan *et al.*, 2014). Our results showed an over expression of Bcl-2 in all tumoral osteoblastic cells from all primitive canine osteosarcoma investigated.

This positive expression suggest that is possible to speculate the inhibition of the mechanism of programmed cell death in according with the neoplastic event. The results obtained during this preliminary study may suggest that the assessment of the degree of expression of Bcl-2 may play an important role in diagnosing neoplastic event but the role of Bcl-2 as a prognostic marker have to be still investigate.

The over expression of Bcl-2 protein in osteosarcoma samples suggests that also alterations of mechanisms of autophagy/apoptosis may have a role in the bone tumor formation, and suggest too that the Bcl-2 protein during the neoplastic process may loss natural action of anti-apoptotic protein that consequently contribute to stimulate the uncontrolled proliferation of tumor cells.

These results suggest that Bcl-2 protein could work first as anti-apoptotic factor that may prepossess proliferative index activity of osteosarcoma and therefore its aggressiveness. We believe that evaluation of Bcl-2 expression may be used as a diagnostic co-marker but its role as a prognostic marker needs to be further investigate. In conclusion this preliminary study reveals that osteoblastic osteosarcoma provide evidence for Bcl-2 expression that suggesting an involvement of this protein in development of this tumor.
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